Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Major Depressive Disorder | Treatment Algorithms | Claims Data Analysis | US | 2014
For the first-line treatment of major depressive disorder (MDD), physicians most commonly prescribe a selective serotonin reuptake inhibitor (SSRI), serotonin/norepinephrine reuptake inhibitor (…
Psoriasis (How Will the Launches of Efficacious Biologics and Novel Oral Agents Affect Psoriasis Treatment and Reimbursement? Insights from U.S. Physicians and Payers) | US | 2014
Psoriasis is a chronic inflammatory skin disorder that is managed with systemic therapies for moderate to severe patients who fail first-line topical therapies and/or phototherapy. Dermatologists…
The Metastatic Castrate-Resistant Prostate Cancer Patient Journey: EU5 Prescribing Preferences and Payer Strategy as Options Diversify | Physician & Payer Forum | EU5 | 2014
Three new premium-priced therapies–Xtandi (Medivation/Astellas Pharma), Provenge (Dendreon), and Xofigo (Algeta/Bayer HealthCare)–have recently been approved in Europe for prostate cancer…
Granulocyte Colony-Stimulating Factors and Monoclonal Antibodies in Oncology (Physician Perspectives) | Biosimilars Advisory Service | US/Eu5/Japan | 2014
European oncologists have had high exposure to biosimilars compared with other European specialists owing to the availability of epoetin alfa and filgrastim biosimilars. Although no biosimilars are…
Wet AMD (The Anti-VEGF Era and Beyond in Wet AMD: The Impact of Clinical Attributes and Market Access Status on Current and Future Prescribing Decisions Among Retinal Specialists) | Physician & Payer Forum | EU5 | 2014
Treatment for the wet (exudative, neovascular) form of age-related macular degeneration (AMD) in Europe is characterized by several current therapies targeting vascular endothelial growth factor (…
Oral HIF-PH Inhibitors for the Treatment of Renal Anemia in CKD Non-Dialysis and Dialysis: How Will U.S. Physicians and Payers Respond to This Novel Class? | Physician & Payer Forum | US | 2014
Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD) that are treated with erythropoiesis-stimulating agents (ESAs) and…
Erythropoiesis-Stimulating Agents, Insulin, and Human Growth Hormone (Physician Perspectives) | Biosimilars Advisory Service | US/EU5/Japan | 2014
Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but…
Hepatitis C Virus: How Will More Efficacious Direct-Acting Antivirals Influence US Prescribing and Reimbursement for This Dynamic Indication? | Physician & Payer Forum | US | 2014
The primary goal of hepatitis C virus (HCV) treatment is to completely eliminate the virus from the patient’s body and thereby reduce or halt the progression of liver fibrosis, preventing further…
